1Wai CT, Fontana R J, Polson J, et al. Clinical outcome and virological characteristics ofhepatitis B-related acute liver failure in the United States. J Viral Hepat,2005,12(2): 192-198.
2Neuberger J. Prediction of survival for patients with fulminant hepatic failure. Hepatology, 2005,41 ( 1 ): 19-22.
3O' Grady JG. Acute liver failure. Postgrad Med J,2005,81(953): 148-154.
5Hwang TH, Yoon BC, Jeong JS, et al. A single administration of denoviralmediated HGF cDNA permits survival of mice from acute hepatic failure.Life Sci,2003,72(7) :851-861.
6Harrison PM, Farzaneh F. Regulation of HGF/SF gene expression in MRC-5 cells by N-acetylcysteine. Biochem Biophys Res Commun, 2000, 279 ( 1 ):108-115.
7Lino S, Toyota J, Kumada H, et al. The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial. J Viral Hepat01,2005,12 (3): 300-306.
8Rolando N, Wade J, Davalos M, et al. The systemic inflammatory response syndrome in acute liver failure. Hepatology, 2000,32(4Pt1 ): 734-739.
9Alonso EM. Acute liver failure in children:the role of defects in fatty acid oxidation. Hepatology, 2005,41 (4): 696-699.
10Bongaerts G, Severijnen R, Timmerman H. Effect of antibiotics, prebiotics and probiotics in treatment for hepatic encephalopathy. Med Hypotheses,2005,64(1) :64-68.
4Y. Takada,S. Ishiguro,K. Fukunaga. Large-animal models of fulminant hepatic failure[J] 2003,Journal of Artificial Organs(1):0009～0013
5Makoto Yoshiba,Kazuhiko Sekiyama,Kazuaki Inoue,Rikiya Fujita. Interferon and cyclosporin A in the treatment of fulminant viral hepatitis[J] 1995,Journal of Gastroenterology(1):67～73
